Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is expected to increase revenue from the sale of its LungFit GO device for the treatment of respiratory diseases, particularly in the midst of a global pandemic. The termination of the deal with XTLBiopharmaceuticals for the NeuroNOS platform may lead to increased strategic exploration and operational focus on the core LungFit nitric oxide delivery franchise. Additionally, Beyond Air's financials show steady revenue growth and a strong potential for further growth in the future.

Bears say

Beyond Air is facing multiple risks, including potentially limited market potential for its products in niche markets, significant financial and capital risks, and potential challenges with commercialization and clinical development. Additionally, the company is dependent on third-parties for distribution and faces risks related to intellectual property, operations, and employees. These factors all contribute to a negative outlook for the company's stock given the high levels of uncertainty and potential for setbacks.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.